V-Prevent

The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event.

This trial is currently in follow-up and is not accepting new patients. To be considered for similar trials, please complete the form below.